DMAC
DiaMedica Therapeutics Inc.
$7.13
-0.51 (-6.68%)
At close · Jul 16
Market Cap
$384.19M
Shares
53,883,345
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $2,727,350 |
| Julie Krop | Chief Medical Officer | $1,707,563 |
| Scott Kellen | CFO | $1,229,520 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $1,550,985 |
| Lorianne Masuoka | CMO | $1,174,310 |
| Scott Kellen | CFO | $813,955 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $1,215,161 |
| Scott Kellen | CFO | $632,215 |
| Kirsten Gruis | Chief Medical Officer | $596,083 |
| Julie Daves | SVP, Clinical Development Operations | $533,370 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $1,080,607 |
| Kirsten Gruis | Chief Medical Officer | $1,004,691 |
| Scott Kellen | CFO | $563,574 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $1,136,169 |
| Scott Kellen | CFO | $546,720 |
| Harry Alcorn | Chief Medical Officer | $545,268 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $878,203 |
| Harry Alcorn | Chief Medical Officer | $509,065 |
| Scott Kellen | CFO | $489,303 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Harry Alcorn | Chief Medical Officer | $778,300 |
| Rick Pauls | CEO | $733,707 |
| Scott Kellen | CFO | $677,807 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Rick Pauls | CEO | $733,707 |
| Scott Kellen | CFO | $642,921 |